Method Development and Validation of Stability Indicating HPLC Assay for the Determination of Tenofovir Alafenamide Fumarate in Tablet Formulation
DOI:
https://doi.org/10.37285/ijpsn.2020.13.6.7Abstract
This manuscript describes the development and validation of a simple, isocratic, precise and accurate HPLC method for the assay of Tenofovir alafenamide fumarate (TAF) in tablet formulations. The previous reported methods were costly, less efficient, utilized temperature and pH conditions for method development, making it more complex while this method utilizes lower quantity of mobile phase, an C18 column to improve efficiency, retention and reproducibility of the method without using the conditions of temperature and pH. The mixture of buffer (0.1% trifluoroacetic acid): ACN (65:35 v/v) was used as a mobile phase with isocratic elution. C18 column (Syncronis C18 250 x 4.6 mm) having particle size 5μm was used at a flow rate of 1mL/min. The suggested method described a linearity range of 30-80 μg/mL and the correlation coefficient equals to 0.997 that determines the linearity between the concentration and absorbance. The tailing factor and plate count were found to be 1.03 and 12110 under the acceptable limits. According to ICH Q2 (R1) guidelines, all parameters were validated except LOD and LOQ. The drug was forcefully degraded by acid, alkali and oxidation. Validated result showed that the method was precise, cheap, isocratic, definite, less time consuming, robust and was degraded within the acceptable limits. No interference was observed in the placebo and blank injections hence the method proved to be specific. The optimum RT (retention time) value was found to be 5.8 min. A simple, efficient and economic method was developed with no use of temperature and pH. The suggested method can be applied as a market analysis of TAF in the tablet form.
Downloads
Metrics
Keywords:
Tenofovir alafenamide, Validation, RP-HPLC, Degradation study, Stability studyDownloads
Published
How to Cite
Issue
Section
References
AbdelHay MH, Gazy AA, Shaalan RA and Ashour HK (2013). Simple spectrophotometric methods for determination of tenofovir fumarate and emtricitabine in bulk powder and in tablets. J Spect 937409: 1-7.
Aggarwal NN, Bhat KI and Jacob JT (2018). Stability Indicating Assay Method Development and Validation for Tenofovir Alafenamide Fumarate by RP-HPLC. Pharm Anal Acta 9: 601.
Arabzadeh V, Sohrabi MR, Goudarzi N and Davallo M (2019). Using artificial neural network and multivariate calibration methods for simultaneous spectrophotometric analysis of Emtricitabine and Tenofovir alafenamide fumarate in pharmaceutical formulation of HIV drug. Spectrochim acta a 215: 266-75.
Buti M, Riveiro-Barciela M and Esteban R (2017). Tenofovir alafenamide fumarate: a new tenofovir prodrug for the treatment of chronic hepatitis B infection. J Infect Dis 216(8): S792-6.
Carr GP and Wahlich JC (1990). A practical approach to method validation in pharmaceutical analysis. J Pharm Aiomed Anal 8(8-12): 613-8.
De Clercq E (2016). Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol 119: 1-7.
Gibson AK, Shah BM, Nambiar PH and Schafer JJ (2016). Tenofovir alafenamide: a review of its use in the treatment of HIV-1 infection. Annal Pharm 50(11): 942-52.
Golla VM, Kurmi M, Shaik K and Singh S (2016). Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate. J Pharm Biomed Anal 131:146-55.
Greig SL and Deeks ED (2016). Elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide: a review in HIV-1 infection. Drugs 76(9): 957-68.
Guo J, Meng F, Li L, Zhong B and Zhao Y (2011). Development and validation of an LC/MS/MS method for the determination of tenofovir in monkey plasma. Biol pharm bull 34(6):877-82.
Gupta SK, Post FA, Arribas JR, Eron Jr JJ, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D (2019). Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS 33(9): 1455.
Hummert P, Parsons TL, Ensign LM, Hoang T and Marzinke MA (2018). Validation and implementation of liquid chromato-graphic-mass spectrometric (LC–MS) methods for the quantification of tenofovir prodrugs. J Pharm Biomed 152: 248-56.
Kokkirala TK and Suryakala D (2019). RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form. J Taibah Univ Sci 13(1): 1137-1146.
Kumar P, Jacob J and Ajina K (2016). Spectroscopic Estimation of Tenofovir Alafenamide, an antiretroviral drug. Res J Pharm Technol 9(5): 538-40.
Lengauer H, Makuc D, Šterk D, Perdih F, Pichler A, Trdan Lušin T, Plavec J and Časar Z (2020). Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates. Pharmaceutics 12(4): 342.
Mastanamma K, Venkata Reddy D, Saidulu P and Varalakhim M (2017). Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of emtricitabine tenofovir alafenamide bulk and their combined dosage form. J Chem Pharm Res 9(9): 70-80.
Ocque AJ, Hagler CE, Morse GD, Letendre SL and Ma Q (2018). Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed 2: 163-9.
Ouyang B, Zhou F, Zhen L, Peng Y, Sun J, Chen Q, Jin X, Wang G and Zhang J (2017). Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC–MS/MS method. J Pharm Biomed 146: 147-53.
Ramaswamy A and Dhas AS (2018). Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC. Arabian J Chem 11(2): 275-81.
Ray AS, Fordyce MW and Hitchcock MJ (2016). Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res 125: 63-70.
Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW and Yale K (2013). Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1–positive adults. J Acq Imm Def Syn 63(4): 449-55.
Scott LJ and Chan HL (2017). Tenofovir alafenamide: a review in chronic hepatitis B. Drugs 77(9): 1017-28.
Shelke A, Shinde M, Mogal R, Sable R and Jadhav A (2018). Application of UV Spectrophotometric methods for simultaneous estimation of Emtricitabine and Tenofovir alafenamide fumarate in bulk. Asian J Pharm Tech 2: 103-7.
Szepesi G, Gazdag M and Mihalyfi K (1991). Selection of high-performance liquid chromatographic methods in pharmaceutical analysis: III. Method validation. J Chromatography Anal 464: 265-78.
Yang B, Xie H, Ran K and Gan Y (2018). Efficient synthesis and resolution of tenofovir alafenamide. Lett Org Chem 15(1): 10-4.
Zhao L, Li Z, Zhou Z, Kang X, Fang B, Ma H and Ge Q (2019). Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic. J Chrom B 1117: 148-57.